Antioxidant defense against antidepressants in C6 and 1321N1 cells

Chemico-Biological Interactions

Volumn 127, Issue 3, 2000, Pages 181-199

  Slamon, N D ^a   Pentreath, V W ^a  

^a UNIVERSITY OF SALFORD   (United Kingdom)

Author keywords

Antidepressants; Antioxidants; Astrocytes; Protection

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUTHIONINE SULFOXIMINE; CYCLIC AMP; FLUOXETINE; GLUTATHIONE; IMIPRAMINE; ISOBUTYLMETHYLXANTHINE; ISOPRENALINE; MONOAMINE OXIDASE INHIBITOR; NEUTRAL RED; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TROLOX C;

ACUTE TOXICITY; ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; ASTROCYTOMA CELL; CELL LINE; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; GLIOMA CELL; HOST RESISTANCE; HUMAN; HUMAN CELL; NONHUMAN; OXIDATIVE STRESS; RAT; SIGNAL TRANSDUCTION;

1-METHYL-3-ISOBUTYLXANTHINE; ADRENERGIC BETA-AGONISTS; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIMETABOLITES; ANTIOXIDANTS; ASTROCYTES; ASTROCYTOMA; BUCLADESINE; BUTHIONINE SULFOXIMINE; CYCLIC AMP; DRUG INTERACTIONS; GLIOMA; GLUTATHIONE; HUMANS; ISOPROTERENOL; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PHOSPHODIESTERASE INHIBITORS; RATS; TUMOR CELLS, CULTURED;

EID: 0034647460     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(00)00172-1     Document Type: Article

References (32)

1. Schwaninger M., Weisbrod M., Knepel W. Progress in defining the mechanism of action of antidepressants. Across receptors and into gene transcription. CNS Drugs. 8:1997;237-243.
2. Baker G.B., Greenshaw A.J. Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system. Cell. Mol. Neurobiol. 9:1989;1-44.
3. Rasenick M.M., Chaney K.A., Chen J. G protein-mediated signal transduction as a target of antidepressant and antibipolar drug action: evidence from model systems. J. Clin. Psychiatry. 57:1996;49-58.
4. Baldessarini R.J. Drugs and the treatment of psychiatric disorders: depression and mania. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Gilman A.G. Goodman and Gilman's the Pharmacological Basis of Therapeutics. nineth ed. 1996;431-461 McGraw-Hill, London.
5. Richardson J.S., Hertz L. The effects of antidepressant drugs on adenylyl cyclase linked beta adrenergic binding sites on mouse astrocytes in primary cultures. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 7:1983;675-680.
6. Hertz L., Richardson J.S. Is neuropharmacology merely the pharmacology of neurons or are astrocytes important too? TIPS Rev. 5:1984;272-276.
7. Eddleston M., Mucke L. Molecular profile of reactive astrocytes - implications for their role in neurologic disease. Neuroscience. 54:1993;15-36.
8. Wilson J.X. Antioxidant defense of the brain: a role for astrocytes. Can. J. Physiol. Pharmacol. 75:1997;1149-1163.
9. Peuchen S., Bolaños J.P., Heales S.J.R., Almeida A., Duchen M.R., Clark J.B. Interrelationships between astrocyte function, oxidative stress and antioxidant status within the central nervous system. Prog. Neurobiol. 52:1997;261-281.
10. Slamon N.D., Pentreath V.W. A comparison of the acute and chronic effects of antidepressants in cultured C6 and 1321N1 cells. ATLA. 26:1998;303-319.
11. Kimelberg H.K., Narumi S., Bourke R.S. Enzymatic and morphological properties of primary rat brain astrocyte cultures and enzyme development in vivo. Brain Res. 153:1978;55-77.
12. Fedoroff S., McAuley W.A.J., Houle J.D., Devon R.M. Astrocyte cell lineage. V. Similarity of astrocytes that form in the presence of dBcAMP in cultures to reactive astrocytes in vivo. J. Neurosci. Res. 12:1984;15-27.
13. Fedoroff S., Ahmed L., Opas M., Kalnins V.I. Organization of microfilaments in astrocytes that form in the presence of dibutyryl cyclic AMP in cultures, and which are similar to reactive astrocytes in vivo. Neuroscience. 22:1987;255-266.
14. Davies D.L., Vernadakis A. Responses in astrocytic C6 glioma cells to ethanol and dibutyryl cyclic AMP. Dev. Brain Res. 24:1986;253-260.
15. Mead C., Pentreath V.W. Hypertrophy and increased glial fibrillary acidic protein are coupled to increased protection against cytotoxicity in glioma cell lines. Toxicol. In Vitro. 12:1998a;141-152.
16. Mead C., Pentreath V.W. Evaluation of toxicity indicators in rat primary astrocytes, C6 glioma and human 1321N1 astrocytoma cells: can gliotoxicity be distinguished from cytotoxicity? Arch. Toxicol. 72:1998b;372-380.
17. Anderson M.E. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol. 113:1985;548-555.
18. Cookson M.R., Pentreath V.W. Protective roles of glutathione in the toxicity of mercury and cadmium compounds to C6 glioma cells. Toxicol. In Vitro. 10:1996;257-264.
19. Cookson M.R., Slamon N.D., Pentreath V.W. Glutathione modifies the toxicity of triethyltin and trimethyltin in C6 glioma cells. Arch. Toxicol. 72:1998;197-202.
20. Legare M.E., Barhoumi R., Burghardt R.C., Tiffany-Castiglioni E. Low-level lead exposure in cultured astroglia: identification of cellular targets with vital fluorescent probes. Neurotoxicology. 14:1993;267-272.
21. Scott J.W., Cort W.M., Harley H. 6-Hydroxychroman-2-carboxylic acids; novel antioxidants. J. Am. Oil Chem. Soc. 51:1974;200-203.
22. Doba T., Burton G.W., Ingold K.U. Antioxidant and co-antioxidant activity of vitamin C either alone or in the presence of a water soluble vitamin E analogue, upon the peroxidation of aqueous multilamellar phospholipid liposomes. Biochim. Biophys. Acta. 835:1985;293-303.
23. Mickle D.A.G. et al. Myocardial salvage with Trolox and ascorbic acid for an acute evolving infarction. Ann. Thorac. Surg. 47:1989;553-557.
24. Barclay L.R.C., Locke S.J., Macneil J.M. Autoxidation in micelles. Synergism of vitamin C with lipid-soluble vitamin E and water-soluble Trolox. Can. J. Chem. 63:1985;366-374.
25. Stark P., Fuller R.W., Wong D.T. The pharmacologic profile of fluoxetine. J. Clin. Psychiatry. 46:1985;7-13.
26. Kimelberg H.K. Receptors on astrocytes - what possible functions? Neurochem. Int. 26:1995;27-40.
27. Caccia S. Metabolism of the newer antidepressants An overview of the pharmacological and pharmacokinetic implications. Clin. Pharmacokinet. 34:1998;281-302.
28. Caccia S., Garattini S. Formation of active metabolites of psychotropic drugs; an updated review of their significance. Clin. Pharmacokinet. 18:1990;434-459.
29. Caccia S., Garattini S. Pharmacokinetic and pharmacodynamic significance of antidepressant drug metabolites. Pharmacol. Res. 26:1992;317-329.
30. Nordin C., Bertilsson L. Active hydroxymetabolites of antidepressants: emphasis on E-10-hydroxy-nortriptyline. Clin. Pharmacokinet. 28:1995;26-40.
31. Stokes P.E., Holtz A. Fluoxetine tenth anniversary update: the progress continues. Clin. Therapeutics. 19:1997;1135-1250.
32. Chen J., Rasenick M.M. Chronic treatment of C6 glioma cells with antidepressant drugs increases functional coupling between a G protein (Gs) and adenylyl cyclase. J. Neurochem. 64:1995;724-732.